Loading
Life sciences · Journal article
Advanced Science · October 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Trastuzumab is the standard first‐line targeted therapy for human epidermal growth factor receptor 2 (HER2)‐positive gastric cancer (GC). Unfortunately, its clinical efficacy is often compromised by the development of drug resistance. The Warburg effect, a hallmark of cancer metabolism, leads to substantial lactate accumulation. Nevertheless, the impact of metabolic reprogramming on the response to HER2‐targeted therapy remains poorly understood. Here, we demonstrate that AARS1‐mediated lactylation of HER2 promotes trastuzumab resistance in GC. Mechanistically, lactylation at lysine 1171 (K1171) promotes USP11‐mediated deubiquitination and stabilization of HER2 and also enhances the interaction between HER2 and EGFR. Clinically, elevated HER2 K1171 lactylation levels are associated with poor prognosis in GC patients. Inhibiting HER2 K1171 lactylation with L‐alanine or stiripentol—a lactate dehydrogenase inhibitor (LDHi) clinically approved for epilepsy—significantly sensitizes tumor cells to trastuzumab. Furthermore, a cell‐penetrating peptide designed to specifically block HER2 K1171 lactylation potently enhances antitumor efficacy in vivo. In summary, our findings identify HER2 lactylation as a critical mechanism underlying trastuzumab resistance and highlight lactate metabolism as a promising therapeutic target for HER2‐positive GC.